Tarlatamab Plus Durvalumab Significantly Reduces Death Risk in Small Cell Lung Cancer

Interim Phase 3 results from the DeLLphi-305 trial, presented at the ESMO 2026 Presidential Symposium and simultaneously published in The New England Journal of Medicine, demonstrated a 58% reduction in the risk of death for patients with extensive-stage small cell lung cancer receiving tarlatamab plus durvalumab as first-line maintenance. The combination extended median overall survival to 21.1 months compared to 12.7 months for durvalumab alone.